Literature DB >> 17701390

[Therapeutic drug monitoring in epileptology and psychiatry].

C Brandt1, P Baumann, G Eckermann, C Hiemke, T W May, B Rambeck, B Pohlmann-Eden.   

Abstract

Experts from epileptology and psychiatry reviewed the current significance of therapeutic drug monitoring (TDM) of antiepileptic drugs and psychiatric drugs in a workshop at Bethel Epilepsy Centre in December 2005. TDM has been essential in epileptology for about 30 years, and it is also increasingly important in psychiatry, in which consensus recommendations were published recently. With regard to cost-cutting in the health system, there are discussions about the financial effect of TDM and outsourcing it to bigger laboratories. In psychiatry it has however been shown that sensibly used TDM may lead to reduced costs. Many issues in TDM require the knowledge and experience of specialised laboratories. The use of TDM data for scientific purposes was discussed at the workshop as well.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17701390     DOI: 10.1007/s00115-007-2325-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  38 in total

1.  The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.

Authors:  Jagdev Sidhu; Sarah Job; Sunita Singh; Richard Philipson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

2.  Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility.

Authors:  F Vuille; M Amey; P Baumann
Journal:  Pharmacopsychiatry       Date:  1991-11       Impact factor: 5.788

Review 3.  Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness.

Authors:  S H Preskorn; G A Fast
Journal:  J Clin Psychiatry       Date:  1991-06       Impact factor: 4.384

4.  Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child.

Authors:  B Rambeck; G Kurlemann; S R Stodieck; T W May; U Jürgens
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 5.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes.

Authors:  M Ingelman-Sundberg
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

7.  Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats.

Authors:  C. Lindsay DeVane; David W. Boulton; Lisa F. Miller; Ronald L. Miller
Journal:  Int J Neuropsychopharmacol       Date:  1999-03       Impact factor: 5.176

8.  Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates.

Authors:  Amal Abou El Ela; Sebastian Härtter; Ulrich Schmitt; Christoph Hiemke; Hildegard Spahn-Langguth; Peter Langguth
Journal:  J Pharm Pharmacol       Date:  2004-08       Impact factor: 3.765

9.  Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

Authors:  Jeffrey H Meyer; Alan A Wilson; Sandra Sagrati; Doug Hussey; Anna Carella; William Z Potter; Nathalie Ginovart; Edgar P Spencer; Andy Cheok; Sylvain Houle
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

Review 10.  An economic evaluation of schizophrenia--1991.

Authors:  R J Wyatt; I Henter; M C Leary; E Taylor
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1995-08       Impact factor: 4.328

View more
  3 in total

1.  [Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy].

Authors:  J Bauer; C Pfeiffer; W Burr
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 2.  Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base.

Authors:  Christian Brandt; Theodor W May; Christian G Bien
Journal:  Ther Adv Neurol Disord       Date:  2016-09-01       Impact factor: 6.570

3.  [Therapeutic drug monitoring of three antiepileptic drugs - Back on twenty years of experience].

Authors:  Samira Serragui; Fatima Zalagh; Driss Soussi Tanani; Lahcen Ouammi; Latifa Ait Moussa; Narjis Badrane; Rachida Soulaymani Bencheikh
Journal:  Pan Afr Med J       Date:  2016-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.